Antiplatelet Drugs Don't Raise Ischemic Hemorrhage Risk

Antiplatelet Drugs Don't Up ICH Risk in New Study
Antiplatelet Drugs Don't Up ICH Risk in New Study

(HealthDay News) – Pre-existing antiplatelet use does not seem to be associated with an increased risk of ischemic hemorrhage (ICH), according to an observational study published in the February issue of Academic Emergency Medicine.

William J Meurer, MD, from the University of Michigan in Ann Arbor, and colleagues collected data from 830 patients (mean age, 69 years) from 28 hospitals from 1996–2004 and from 2007–2010, to examine whether pre-existing antiplatelet therapy use correlates with the risk of ICH following acute stroke thrombolysis.

The researchers found that 47% of participants had documented pre-existing antiplatelet treatment. In unadjusted analyses, the proportions of patients with any ICH and with symptomatic ICH (sICH) were increased with antiplatelet use (absolute risk difference, 4.2% and 3.1%, respectively). After adjustment for confounders, there was no correlation between antiplatelet use and radiographic ICH or sICH. The risk of radiographic ICH was increased for patients aged ≥81 years. In meta-analyses combining these findings with previous research, the unadjusted risk of radiographic ICH and sICH were increased with antiplatelet treatment (absolute risk difference, 4.9% and 4%, respectively). After adjustment, there was a significantly increased likelihood of sICH with antiplatelet use (odds ratio, 1.6)

"[We] did not find that pre-existing antiplatelet use was associated with post-thrombolysis ICH or sICH in this cohort of community treated patients," the authors write. "The meta-analyses demonstrated small, but statistically significant, increases in the absolute risk of radiographic ICH and sICH, along with increased odds of sICH in patients with pre-existing antiplatelet use."

Abstract
Full Text (subscription or payment may be required)
Commentary (subscription or payment may be required)